SAN FRANCISCO, Nov. 10, 2015 /PRNewswire/ -- Exagen, a privately held diagnostic company with offices in Vista, California and Albuquerque, New Mexico announced today that five abstracts were presented at the 2015 annual meeting of the American College of Rheumatology (ACR), held November 6-11 in San Francisco, CA. Two of the five abstracts were also selected for podium presentation (Wallace & Askanase).
The information presented demonstrates the company's continued commitment to further develop diagnostic, prognostic and drug monitoring testing services for the optimization of patient treatment.
About Exagen
Exagen Diagnostics, Inc. is a commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune Connective Tissue Disease (CTD). Exagen's mission with the Avise product line is to help physicians provide accurate, timely diagnosis and optimization for the treatment of autoimmune CTD. For more information, please visit www.exagen.com.
Contact: Blythe Lawton
760.560.1506 – info@exagen.com
SOURCE Exagen Diagnostics, Inc.